Alan Katz
Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Radiosurgery | 6 | 2006 | 24 |
Why?
|
Neoplasm Metastasis | 4 | 2006 | 112 |
Why?
|
Liver Neoplasms | 4 | 2006 | 97 |
Why?
|
Neoplasms, Second Primary | 3 | 1996 | 31 |
Why?
|
Radiotherapy | 2 | 2000 | 73 |
Why?
|
Lung Neoplasms | 5 | 2000 | 159 |
Why?
|
Endometrial Neoplasms | 1 | 2001 | 18 |
Why?
|
Vagina | 1 | 2001 | 30 |
Why?
|
Brachytherapy | 4 | 2000 | 32 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2001 | 55 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2000 | 31 |
Why?
|
Carcinoma, Merkel Cell | 4 | 1996 | 7 |
Why?
|
Skin Neoplasms | 5 | 1996 | 97 |
Why?
|
Aged, 80 and over | 13 | 1997 | 599 |
Why?
|
Retrospective Studies | 10 | 1997 | 653 |
Why?
|
Hodgkin Disease | 1 | 2000 | 46 |
Why?
|
Dose Fractionation | 5 | 2006 | 25 |
Why?
|
Aged | 19 | 1996 | 988 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2000 | 118 |
Why?
|
Breast Neoplasms | 2 | 2000 | 185 |
Why?
|
Stereotaxic Techniques | 2 | 2006 | 24 |
Why?
|
Whole-Body Irradiation | 2 | 2006 | 43 |
Why?
|
Tumor Burden | 3 | 2006 | 12 |
Why?
|
Middle Aged | 17 | 1996 | 1161 |
Why?
|
Adult | 17 | 1996 | 1317 |
Why?
|
Brain Neoplasms | 2 | 2006 | 116 |
Why?
|
Female | 19 | 1996 | 1643 |
Why?
|
Humans | 25 | 1996 | 1856 |
Why?
|
Airway Obstruction | 2 | 2000 | 29 |
Why?
|
Radiotherapy Dosage | 6 | 2000 | 55 |
Why?
|
Neoplasm Staging | 3 | 2001 | 125 |
Why?
|
Feasibility Studies | 2 | 2006 | 144 |
Why?
|
Sarcoma, Kaposi | 2 | 1998 | 15 |
Why?
|
Thoracic Neoplasms | 1 | 2009 | 16 |
Why?
|
Remission Induction | 2 | 2003 | 64 |
Why?
|
Rectal Neoplasms | 1 | 2010 | 26 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2009 | 25 |
Why?
|
Radiation Injuries | 2 | 2006 | 63 |
Why?
|
Male | 17 | 1996 | 1553 |
Why?
|
Treatment Outcome | 8 | 1997 | 661 |
Why?
|
Neoplasms | 2 | 1999 | 239 |
Why?
|
Bone Neoplasms | 2 | 2006 | 83 |
Why?
|
Glioma | 1 | 2008 | 51 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 1997 | 121 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2006 | 111 |
Why?
|
Tumor Markers, Biological | 1 | 2006 | 112 |
Why?
|
Survival Analysis | 5 | 1996 | 205 |
Why?
|
Pilot Projects | 3 | 2008 | 264 |
Why?
|
Survival Rate | 3 | 2009 | 250 |
Why?
|
Etoposide | 2 | 1997 | 37 |
Why?
|
Fluorouracil | 2 | 1997 | 49 |
Why?
|
Bronchial Diseases | 1 | 2001 | 9 |
Why?
|
Adenocarcinoma | 1 | 2006 | 167 |
Why?
|
Radiodermatitis | 1 | 2001 | 6 |
Why?
|
Lung Diseases, Obstructive | 1 | 2001 | 30 |
Why?
|
Constriction, Pathologic | 1 | 2001 | 65 |
Why?
|
Dermatologic Agents | 1 | 2001 | 15 |
Why?
|
Sesquiterpenes | 1 | 2001 | 24 |
Why?
|
Palliative Care | 2 | 1999 | 65 |
Why?
|
Umbilicus | 1 | 2000 | 4 |
Why?
|
Medical Records | 1 | 2001 | 104 |
Why?
|
Cholecystectomy | 1 | 2000 | 16 |
Why?
|
Abdominal Neoplasms | 1 | 2000 | 20 |
Why?
|
Gallbladder Neoplasms | 1 | 2000 | 7 |
Why?
|
Fatty Acids | 1 | 2001 | 48 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2000 | 11 |
Why?
|
Lipids | 1 | 2001 | 97 |
Why?
|
Prospective Studies | 3 | 2008 | 545 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1999 | 29 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 78 |
Why?
|
Carcinoma | 1 | 2000 | 109 |
Why?
|
Laparoscopy | 1 | 2000 | 52 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2006 | 85 |
Why?
|
Melanoma | 1 | 1999 | 87 |
Why?
|
Treatment Failure | 2 | 2006 | 88 |
Why?
|
Multivariate Analysis | 3 | 1997 | 225 |
Why?
|
Israel | 3 | 1996 | 20 |
Why?
|
Cisplatin | 3 | 1997 | 43 |
Why?
|
Lymphatic Metastasis | 3 | 1997 | 77 |
Why?
|
Tomography, X-Ray Computed | 2 | 2006 | 321 |
Why?
|
Follow-Up Studies | 2 | 2003 | 553 |
Why?
|
Medical Illustration | 1 | 2010 | 8 |
Why?
|
Radiation Oncology | 1 | 2010 | 11 |
Why?
|
Radiotherapy, Conformal | 1 | 2010 | 12 |
Why?
|
Prognosis | 2 | 1997 | 388 |
Why?
|
Observer Variation | 1 | 2010 | 103 |
Why?
|
Gastrointestinal Tract | 1 | 2009 | 26 |
Why?
|
Jews | 2 | 1996 | 10 |
Why?
|
Combined Modality Therapy | 2 | 1997 | 219 |
Why?
|
Kaplan-Meier Estimate | 1 | 2008 | 89 |
Why?
|
Comorbidity | 1 | 2009 | 190 |
Why?
|
Double-Blind Method | 1 | 2010 | 274 |
Why?
|
Disease Progression | 1 | 2009 | 244 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2006 | 9 |
Why?
|
Antineoplastic Protocols | 1 | 2006 | 3 |
Why?
|
Kidney | 1 | 2009 | 223 |
Why?
|
Emulsions | 1 | 2001 | 6 |
Why?
|
Skin Pigmentation | 1 | 2001 | 8 |
Why?
|
Mastectomy, Segmental | 1 | 2001 | 16 |
Why?
|
Administration, Topical | 1 | 2001 | 57 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2001 | 30 |
Why?
|
Tamoxifen | 1 | 2001 | 38 |
Why?
|
Iridium Radioisotopes | 1 | 2000 | 11 |
Why?
|
Fiber Optic Technology | 1 | 2000 | 18 |
Why?
|
Postoperative Period | 1 | 2000 | 63 |
Why?
|
Bronchoscopy | 1 | 2000 | 27 |
Why?
|
Mitomycin | 1 | 1999 | 13 |
Why?
|
Carboplatin | 1 | 1999 | 16 |
Why?
|
Bleomycin | 1 | 1999 | 28 |
Why?
|
Ethnic Groups | 1 | 2001 | 95 |
Why?
|
Infusions, Intravenous | 1 | 1999 | 87 |
Why?
|
Arabs | 1 | 1998 | 2 |
Why?
|
Administration, Oral | 1 | 2000 | 170 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1999 | 49 |
Why?
|
Incidence | 1 | 2001 | 336 |
Why?
|
Immunocompromised Host | 1 | 1998 | 70 |
Why?
|
Radiotherapy, High-Energy | 1 | 1997 | 16 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1997 | 39 |
Why?
|
Vincristine | 1 | 1997 | 27 |
Why?
|
Methotrexate | 1 | 1997 | 40 |
Why?
|
Sunlight | 1 | 1996 | 12 |
Why?
|
Doxorubicin | 1 | 1997 | 60 |
Why?
|
Cyclophosphamide | 1 | 1997 | 82 |
Why?
|
Sex Distribution | 1 | 1996 | 101 |
Why?
|
Practice Guidelines as Topic | 1 | 1999 | 174 |
Why?
|
Dose-Response Relationship, Drug | 1 | 1999 | 431 |
Why?
|
Age Distribution | 1 | 1996 | 127 |
Why?
|
Registries | 1 | 1996 | 83 |
Why?
|
Analysis of Variance | 1 | 1997 | 339 |
Why?
|
Time Factors | 1 | 1999 | 896 |
Why?
|
Adolescent | 1 | 1999 | 891 |
Why?
|
